invIOs presents positive patient data from ongoing Phase 1b trial of APN401 cell therapy in advanced solid tumors at SITC 2022
10 nov. 2022 09h40 HE
|
invIOs GmbH
Poster presentation shows treatment with APN401, an autologous cell therapy product targeting the master immune checkpoint Cbl-b, resulted in stabilization of disease for more than six months in a...
Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors
07 nov. 2022 08h05 HE
|
Lyell Immunopharma, Inc
Preclinical data demonstrate genetic and epigenetic reprogramming can ameliorate T cell exhaustion and enhance stem-like qualities and potency of T cells in various modalities SOUTH SAN FRANCISCO,...
Lyell Immunopharma Reports Second Quarter Financial Results and Business Highlights
04 août 2022 16h05 HE
|
Lyell Immunopharma, Inc
Cash, cash equivalents and marketable securities of $787.0 million as of June 30, 2022 provides funding into 2025 and supports advancement of multiple product candidates through key clinical...
Global Oncology Based In-Vivo CRO Market (2022 to 2027) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts
19 juil. 2022 05h59 HE
|
Research and Markets
Dublin, July 19, 2022 (GLOBE NEWSWIRE) -- The "Oncology Based In-Vivo CRO Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to...
Global NGS Oncology Market Report 2022-2032: Increasing Incidence of Cancer Requiring Sophisticated Molecular Techniques Driving Growth
13 juil. 2022 07h43 HE
|
Research and Markets
Dublin, July 13, 2022 (GLOBE NEWSWIRE) -- The "NGS Oncology Market - A Global and Regional Analysis: Focus on Offering, Sequencing Technology, Workflow, Application, End User, and Region - Analysis...
Global Radioligand Therapy Markets, 2020-2021 & 2022-2031: Expanding Radiopharmaceutical Coverage & Radioligand Therapy Demand Inclined by Rising Prevalence of Cancer
11 mai 2022 04h03 HE
|
Research and Markets
Dublin, May 11, 2022 (GLOBE NEWSWIRE) -- The "Radioligand Therapy Market - A Global and Regional Analysis: Focus on Indication, Product, Biomarker, and Region - Analysis and Forecast, 2021-2031"...
Global Immune Checkpoint Inhibitors Market to 2027 - Size, Share & Industry Trends Analysis Report
26 avr. 2022 06h43 HE
|
Research and Markets
Dublin, April 26, 2022 (GLOBE NEWSWIRE) -- The "Global Immune Checkpoint Inhibitors Market Size, Share & Industry Trends Analysis Report By Application (Lung Cancer, Bladder Cancer, Melanoma,...
Lyell Immunopharma Announces Upcoming Presentation on LYL797 at the American Association for Cancer Research (AACR) 2022 Annual Meeting
08 mars 2022 16h45 HE
|
Lyell Immunopharma, Inc
LYL797 is an investigational ROR1 CAR T-cell therapy incorporating novel reprogramming technologies for solid tumors SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Lyell...
Lyell Immunopharma Appoints Gary Lee, Ph.D. as Chief Scientific Officer
31 janv. 2022 16h05 HE
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with...
Global Oncology Based In-vivo CRO Markets to 2028 by Indication (Blood Cancer, Solid Tumor), Model (Syngeneic Model, Patient Derived Xenograft (PDX), Xenograft),
15 oct. 2021 05h08 HE
|
Research and Markets
Dublin, Oct. 15, 2021 (GLOBE NEWSWIRE) -- The "Global Oncology Based In-vivo CRO Market Size, Share & Trends Analysis Report by Indication (Blood Cancer, Solid Tumor), by Model (Syngeneic Model,...